Ranjit Manchanda (MD, MRCOG, PhD) is a Clinical Senior Lecturer at Barts Cancer Institute, QMUL, and Consultant Gynaecological Oncologist at Barts and the Royal London Hospital.
Ranjit’s research interests are focused around population based germline testing and precision medicine approaches for risk prediction, stratification, and targeted screening & cancer prevention. He has a keen research interest in health economic issues related to his areas of research. He is the Principal Investigator on the PROTECTOR trial (salpingectomy for ovarian cancer prevention in high-risk women), PROMISE Pilot study (Feasibility of population-based risk prediction and stratification for targeted ovarian cancer screening and prevention), GCaPPS trial (RCT on population based BRCA testing in the Jewish population), and SIGNPOST study (evaluating outcomes of germline panel and somatic tumour testing in ovarian cancer). He leads the Barts Women’s Precision Medicine and Cancer Prevention Team and chairs the Barts Health Gynae-oncology trials group. He is co-Lead for the Cancer Prevention Theme at the Barts CRUK Cancer Centre. He is a member of the NCRI Ovarian Cancer Surgical Sub group, and a number of other advisory bodies and oversight committees. He has served as President of the European Network of Young Gynaecological Oncologists (ENYGO) and member of the European Society of Gynaecological Oncology (ESGO) Council from 2011-2013. He has a strong interest in training in gynaecological oncology and led a number of training initiatives in and outside Europe. He is a member of the International Gynecological Cancer Society (IGCS) Education Steering Committee and BGCS International Subcommittee. He is the Integrated Academic Training Programme Director for North Central and North East London, London Specialty School of Obstetrics & Gynaecology.